Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/59061
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSermsiri Sangroongruangsrien_US
dc.contributor.authorUsa Chaikledkaewen_US
dc.contributor.authorSuthasinee Kumluangen_US
dc.contributor.authorOlivia Wuen_US
dc.contributor.authorClaudia Geueen_US
dc.contributor.authorTanapat Ratanapakornen_US
dc.contributor.authorPattara Leelahavarongen_US
dc.contributor.authorLily Ingsrisawangen_US
dc.contributor.authorPaisan Ruamviboonsuken_US
dc.contributor.authorWongsiri Taweebanjongsinen_US
dc.contributor.authorJanejit Choovuthayakornen_US
dc.contributor.authorApichart Singalavanijaen_US
dc.contributor.authorPrut Hanutsahaen_US
dc.contributor.authorKittisak Kulvichiten_US
dc.contributor.authorThitiporn Ratanapojnarden_US
dc.contributor.authorWarapat Wongsawaden_US
dc.contributor.authorYot Teerawattananonen_US
dc.date.accessioned2018-09-05T04:37:13Z-
dc.date.available2018-09-05T04:37:13Z-
dc.date.issued2018-01-01en_US
dc.identifier.issn11791918en_US
dc.identifier.issn11732563en_US
dc.identifier.other2-s2.0-85051263294en_US
dc.identifier.other10.1007/s40261-018-0678-5en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85051263294&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/59061-
dc.description.abstract© 2018, The Author(s). Background: There is very limited evidence examining serious systemic adverse events (SSAEs) and post-injection endophthalmitis of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) treatments in Thailand and low- and middle-income countries. Moreover, findings from the existing trials might have limited generalizability to certain populations and rare SSAEs. Objectives: This prospective observational study aimed to assess and compare the safety profiles of IVB and IVR in patients with retinal diseases in Thailand. Methods: Between 2013 and 2015, 6354 patients eligible for IVB or IVR were recruited from eight hospitals. Main outcomes measures were prevalence and risk of SSAEs, mortality, and endophthalmitis during the 6-month follow-up period. Results: In the IVB and IVR groups, 94 and 6% of patients participated, respectively. The rates of outcomes in the IVB group were slightly greater than in the IVR group. All-cause mortality rates in the IVB and IVR groups were 1.10 and 0.53%, respectively. Prevalence rates of endophthalmitis and non-fatal strokes in the IVB group were 0.04% of 16,421 injections and 0.27% of 5975 patients, respectively, whereas none of these events were identified in the IVR group. There were no differences between the two groups in the risks of mortality, arteriothrombotic events (ATE), and non-fatal heart failure (HF). Adjustment for potential confounding factors and selection bias using multivariable models for time-to-event outcomes and propensity scores did not alter the results. Conclusions: The rates of SAEs in both groups were low. The IVB and IVR treatments were not associated with significant risks of mortality, ATE, and non-fatal HF. Trial Registration: Thai Clinical Trial Registry identifier TCTR20141002001.en_US
dc.subjectMedicineen_US
dc.titleReal-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Studyen_US
dc.typeJournalen_US
article.title.sourcetitleClinical Drug Investigationen_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsThailand Ministry of Public Healthen_US
article.stream.affiliationsUniversity of Glasgowen_US
article.stream.affiliationsKhon Kaen Universityen_US
article.stream.affiliationsKasetsart Universityen_US
article.stream.affiliationsRangsit Universityen_US
article.stream.affiliationsMettapracharak (Wat Rai Khing) Hospitalen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsChulalongkorn Universityen_US
article.stream.affiliationsPhramongkutklao College of Medicineen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.